Drug Overview
Dupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. This is a novel mechanism of action for the treatment of severe asthma, with the majority of marketed biologics targeting IL-5.
Dupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. This is a novel mechanism of action for the treatment of severe asthma, with the majority of marketed biologics targeting IL-5.
Table of Contents
Product ProfilesDupixent: Asthma
Dupixent: Atopic dermatitis
List of Figures
Figure 53: Trelegy Ellipta for asthma - SWOT analysis
Figure 54: Drug assessment summary of Trelegy Ellipta in asthma
Figure 55: Drug assessment summary of Trelegy Ellipta in asthma
Figure 56: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 56: Xolair for asthma - SWOT analysis
Figure 6: Drug assessment summary of Dupixent in atopic dermatitis
Figure 7: Drug assessment summary of Dupixent in atopic dermatitis
List of Tables
Table 1: Dupixent drug profile
Table 2: Dupixent Phase III data in asthma
Table 3: Dupixent Phase III trials in asthma
Table 4: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Dupixent drug profile
Table 50: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
